STAAR Surgical Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 17, 2025, details a significant realignment of the leadership structure at STAAR Surgical Company (STAA). The report covers executive appointments, departures, and corresponding amendments to the Company's bylaws effective March 17, 2025.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, or margins. However, it discloses specific compensation and severance figures related to the leadership changes:
- Warren Foust (New President & COO): Granted 29,326 Restricted Stock Units (RSUs) vesting over three years and 29,326 Performance Stock Units (PSUs) with a 0%-200% target vesting schedule based on revenue performance through December 31, 2027.
- Deborah Andrews (Interim CFO): Salary set at $150,000 per month for March, April, and May 2025, reducing to $100,000 per month thereafter. No equity award granted.
- Patrick Williams (Outgoing CFO): Eligible for a lump-sum severance of $575,000 (12 months of base salary) plus 12 months of health benefits. A three-month consulting agreement at $47,917 per month is also in place.
- Keith Holliday (Outgoing CTO): Eligible for a lump-sum severance of $550,110 (12 months of base salary) plus 12 months of health benefits.
Material Changes
The primary material change is the restructuring of the executive team:
- Appointments: Warren Foust promoted to President and Chief Operating Officer. Deborah Andrews appointed as Interim Chief Financial Officer. Magda Michna, PhD, promoted to the newly created role of Chief Development Officer, assuming oversight of Quality and R&D in addition to clinical and regulatory affairs.
- Departures: Patrick Williams stepped down as CFO. Keith Holliday, PhD, retired as Chief Technology Officer. Stephen C. Farrell remains CEO but relinquished the title of President.
- Bylaw Amendments: The Board amended the Company's bylaws to allow the CEO and President to be separate officers, formally established the CFO as an officer, and renamed the Chairman of the Board to Chair of the Board.
Outlook, Risks, and Management Commentary
The Board initiated a search for a permanent Chief Financial Officer to replace the interim appointment. The filing explicitly states that the departure of Patrick Williams is not the result of any disagreement regarding financial reporting, accounting policies, or internal controls. No specific financial guidance or forward-looking revenue projections were included in this filing.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent CFO.
- Review the specific revenue performance targets attached to Warren Foust's Performance Stock Units (PSUs).
- Confirm the execution of separation agreements and general releases required for Patrick Williams and Keith Holliday to receive their severance packages.
- Monitor the transition of R&D and Quality functions under the new Chief Development Officer.